anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Comparing the differences in efficacy and adverse reactions on the application between tunnel peripherally inserted central catheter (TPICC) and ultrasound-guided peripherally inserted central catheter (PICC) in patients with advanced tumors. A retrospective investigation was conducted to collect treatment data. We randomly selected 200 patients with advanced tumors who were admitted to our hospital from January 2020 to January 2022 as the research subjects. The observation group consisted of 100 cases of tunnel PICC catheterization, while the control group consisted of 100 cases of PICC catheterization. We observed and compared the catheterization time, PICC puncture success rate, intraoperative blood loss, pain degree, comfort level, and postoperative complication rate between the 2 groups. Compared with the control group, there was no significant difference at the distribution of PICC indwelling time in the observation group, and the difference was not statistically significant (P > .05). The success rate on PICC puncture in the observation group was higher than that on the control group (P < .05). Intraoperative bleeding volume and numerical rating scale (NRS) of the observation group were lower than those of the control group (P < .05). At 1 month postoperatively, comfort ratings in the observation group and the control group were lower than those of their same groups at 1 week postoperatively (P < .05); At 1 week and 1 month postoperatively, comfort rating in the observation group were lower than that in the control group (P < .05). The incidence of postoperative complication in the observation group was lower than that in the control group (P < .05). TPICC improves the success rate on puncture and the post-catheterization comfort, it reduces NRS and the risks on complications, which owns high safety.
The invention discloses a traditional Chinese medicine composition with yin nourishing, yang assisting, vital essence reinforcing, and primordial qi strengthening efficacies, a preparation method thereof, and a purpose thereof. The traditional Chinese medicine composition provided by the invention is composed of 59 medicine materials. The medicine materials provide synergetic effects of yin nourishing, yang assisting, vital essence reinforcing, and primordial qi strengthening. The traditional Chinese medicine composition is used for treating viscera functional disturbance, qi-blood deficiency and yin-yang deficiency with symptoms of pale face, severe palpitation, fatigue, easy wheeze, frequent long breathe, chilly feeling, cold extremities, amnesia, insomnia, dreaminess, burning sensation of five centers, night sweat, spontaneous perspiration, dizziness, poor appetite, loose stool, constipation, menoxenia, and frequent urinate or frequent nocturia. The traditional Chinese medicine composition contains a plurality of medicine materials, but the medicine materials are not disordered. With the formula, yin-nourishing medicine materials assists in nourishing yin with the aid of yang, and yang-nourishing medicine materials assists in nourishing yang with the aid of yin. The traditional Chinese medicine composition provided by the invention can be a model for yin-yang regulating, vital essence reinforcing, primordial qi strengthening, spleen and kidney covering, and heart and kidney balancing tonic preparations. As results of experiments, with the medicine composition provided by the invention, SDH activity can be substantially improved; LDH level can be reduced; serum gastrin content of rat with spleen qi deficiency can be increased; liver glycogen content of mice after weight-bearing swimming is increased; and serum LA level of mice after weight-bearing swimming is reduced. Thus, the traditional Chinese medicine composition provides better effects in age resisting, yang invigorating, and qi benefiting.
The present invention relates to Chinese patent medicine for treating rheumatic diseases and rheumatoid diseases and a preparation method thereof. The Chinese patent medicine is prepared from traditional Chinese medicine as raw materials. The present invention is characterized in that the Chinese patent medicine comprises Chinese herbal medicine comprising the following components as raw materials: silky ant, curculigo rhizome, parched white mustard seed, black-tail snake, gastrodia tuber, Chinese ephedra, cinnamon, deglued antler, parched pangolin scale, angelica, notoginseng, keel and dried ginger. The present invention has the advantages of no toxic and side effect, small dosage and short treatment cycle. The effective rate of the present invention can reach 97%. The present invention can make the immunity of patients largely improved, and can be widely applied to treating various kinds of rheumatic diseases and rheumatoid diseases.
193,831. Agopian, L. A. Feb. 23, 1922, [Convention date]. Addition to 168,903. Extracts, making.- Comprises two modifications of the process described in the parent Specification for obtaining vitamines. (1) Citric, tartaric, or acetic acid is substituted for the neutral salts of copper. lead, mercury or silver. When employing nitric and tartaric acids, the vegetables are dusted with the powdered acid prior to the crushing; in the case of acetic acid, the addition is made to the vegetable juices. The acids are removed before the extraction treatment. (2) The use in the Soxhlet apparatus of glycerine as the solvent. The material to be extracted is placed in the lower vessel 14 and the whole apparatus is filled with glycerine; owing to the difference in temperature between the bath 19 and the cooling coil 18, the glycerine circulates in the apparatus and ultimately deposits the C vitamine on a filter paper in the vessel 11. The Specification as open to inspection under Sect. 91 (3) (a) describes also the extraction of the A vitamine from both the expressed juices of vegetable and from the solid residue after expression. The juices are treated with the organic acids, and the solvents employed for the extraction are benzene, petroleum ether, ethyl ether, acetic ether, acetone and chloroform. To obtain the A vitamine from the vegetable residue, the latter is desiccated in vacuo in the presence of sulphuric acid and then extracted with the solvents. This subject-matter does not appear in the Specification as accepted.
Patients will not undergo any postoperative intervention. Then, their pain will be evaluated with the Visual analog scale at the 6th hour, 12th hour, 24th hour and at discharge.
Watchful Waiting

Watchful waiting has the advantage that no therapy may ever be required. For patients with silent or minimally symptomatic stones, the rate of development of moderate-to-severe symptoms or gallstone complications is estimated to be between 2% and 6% per year, leading to a cumulative rate of 7% to 27% in 5 years. Presumably the rate is higher for patients already having symptoms.

Cholecystectomy

For patients with symptomatic gallstones, surgery offers the advantage of immediate and permanent stone removal, but carries a high risk in some patients. About 5% of cholecystectomized patients have residual symptoms or retained common duct stones. The spectrum of surgical risk varies as a function of age and the presence of disease other than cholelithiasis.

Women in good health or who have only moderate systemic disease and are under 49 years of age have the lowest surgical mortality rate (0.054); men in all categories have a surgical mortality rate twice that of women. Common duct exploration quadruples the rates in all categories. The rates rise with each decade of life and increase tenfold or more in all categories with severe or extreme systemic disease.
The immune system plays a crucial role in protecting the body from invading pathogens and maintaining tissue homoeostasis. Maintaining homoeostatic lipid metabolism is an important aspect of efficient immune cell function and when disrupted immune cell function is impaired. There are numerous metabolic diseases whereby systemic lipid metabolism and cellular function is impaired. In the context of metabolic disorders, chronic inflammation is suggested to be a major contributor to disease progression. A major contributor to tissue dysfunction in metabolic disease is ectopic lipid deposition, which is generally caused by diet and genetic factors. Thus, we propose the idea, that similar to tissue and organ damage in metabolic disorders, excessive accumulation of lipid in immune cells promotes a dysfunctional immune system (beyond the classical foam cell) and contributes to disease pathology. Herein, we review the evidence that lipid accumulation through diet can modulate the production and function of immune cells by altering cellular lipid content. This can impact immune cell signalling, activation, migration, and death, ultimately affecting key aspects of the immune system such as neutralising pathogens, antigen presentation, effector cell activation and resolving inflammation.
Isotretinoin, a retinoid, is available as Myorisan in 10-mg, 20-mg and 40-mg soft gelatin capsules for oral administration. Each capsule contains yellow wax, butylated hydroxyanisole, edetate disodium, hydrogenated vegetable oil, tocopherol, and soybean oil. Gelatin capsules contain gelatin, glycerin and non-crystallizing sorbitol solution, with the following dye systems: 10 mg — ferric oxide (yellow) and titanium dioxide; 20 mg — titanium dioxide; 40 mg — FD&C Yellow No.6 and titanium dioxide.

The edible imprinting ink for all the capsules contains: shellac glaze, dehydrated alcohol, isopropyl alcohol, iron oxide black, N-butyl alcohol, propylene glycol, and ammonium hydroxide. 

USP Dissolution Test Pending.

Chemically, isotretinoin is 13-cis-retinoic acid and is related to both retinoic acid and retinol (vitamin A). It is a yellow to orange crystalline powder with a molecular weight of 300.44. The structural formula is:
1498913 Pharmaceutical compositions containing magnesium salts VERLA-PHARM ARZNEIMITTEL - FABRIK APOTHEKER HJV EHRLICH 18 Feb 1976 [20 Feb 1975] 06422/76 Heading A5B Pharmaceutical compositions for oral or parenteral administration comprise a mixture of (a) magnesium diglutamate or magnesium diaspartate, and (b) an alkali metal halide, a magnesium halide or an alkaline earth metal halide, optionally together with a pharmaceutical carrier or diluent. The components (a) and (b) are preferably in a 1:1 molar ratio. The halides (b) can be the chloride, bromide or iodide of magnesium, sodium, potassium or calcium, or lithium chloride or bromide or strontium chloride. The carrier is preferably a hydrophilic substance e.g. a water-soluble carbohydrate, mucoid, protein, alcohol or polyalcohol, or polyvinyl pyrrolidone or silica gel. The compositions may be layered tablets of a layer of (a) and a layer of (b), or as loose granulates or oral or parenteral solutions. They have muscle-relaxant, sedative or tranquillising activity, or are used for prophylaxis of infarcts or thyroid disorders, or for treatment of electrolyte imbalance. The strontium-containing compositions may be used in therapy of radio-strontium (Sr<SP>90</SP>) treatment to lower bone levels of Sr<SP>90</SP>, and the lithium salt compositions have anti-depressant activity.
Adults - In general, clinically significant responses are not seen at doses below 1500 mg per day. However, a lower recommended starting dose and gradually increased dosage is advised to minimize gastrointestinal symptoms.  
  
The usual starting dose of metformin hydrochloride tablets is 500 mg twice a day or 850 mg once a day, given with meals. Dosage increases should be made in increments of 500 mg weekly or 850 mg every 2 weeks, up to a total of 2000 mg per day, given in divided doses. Patients can also be titrated from 500 mg twice a day to 850 mg twice a day after 2 weeks. For those patients requiring additional glycemic control, metformin hydrochloride tablets may be given to a maximum daily dose of 2550 mg per day. Doses above 2000 mg may be better tolerated given three times a day with meals.  
  
Pediatrics – The usual starting dose of metformin hydrochloride tablets is 500 mg twice a day, given with meals. Dosage increases should be made in increments of 500 mg weekly up to a maximum of 2000 mg per day, given in divided doses.
FIELD: medicine. SUBSTANCE: the synthesis is carried out by reacting p-oxycinnamic acid and α-bromocaproic acid in the presence of sodium hydroxy on heating. The field 80%, mp 190-191 C, the empirical formula CHO. As compared with the activity of 4-carboxymethylenoxycinnamic acid and papaverine hydrochloride, the hypotensive activity of the new compound (after 60 min) is higher by 1.7 and 2.6 times. The toxicity LD>3000 mg/kg is similar to the toxicity of the structural analogue, but less than LDof papaverine hydrochloride (500 mg/kg). EFFECT: new and more active compounds of said class. 1 tbl
This is a phase II step-wise, randomized, multicenter, double-blind and controlled clinical trial to evaluate the safety and immunogenicity of an attenuated tetravalent lyophilized dengue vaccine manufactured by Butantan Institute. A total of 300 volunteers will be recruited including men and no pregnant/breastfeeding women between 18 and 59 years of age complete, with and without previous exposure to dengue that will be randomized into Step A and Step B. Step A will include 50 volunteers with no previous exposure and they will be randomly assigned to receive one dose of either the lyophilized formulation (Butantan), or the liquid formulation (TetraVax-DV Vaccine - Admixture TV003 developed by NIH/NIAID and produced and formulated at Butantan according the NIH-Protocol), or the placebo. A second dose will be administered six months after the first vaccination as part of an exploratory assessment. Step B will include 250 participants(50 without previous exposure to dengue,and 200 with previous exposure to dengue) who will be randomly assigned to receive one dose of either the lyophilized formulation (Butantan),or the placebo. All participants included in both steps will be followed by a period of five years after their inclusion in the study. The vaccines will be administered at dose of 1000 PFU (for each of the vaccine viruses),and both vaccines and the placebo will be administered subcutaneously.
This site will receive 500 nM aBQ-123, an inhibitor of endothelin type A receptors. This site will additionally receive 20mM L-NAME and 28mM SNP to inhibit nitric oxide (NO) production and elicit vasodilation, respectively, to assess NO contribution and maximal vasodilation.
Patients should receive the following information and instructions: 

  1. This drug has been prescribed to perform an X-ray of the gastrointestinal tract. 
  2. Inform the physician if pregnant or if allergic to iodine, any foods, or X-ray materials. 
  3. The iodine in diatrizoate salts may interfere with some thyroid tests if these are needed in the future. Inform the attending physician at that time about this gastrointestinal study. 
  4. This drug may cause abdominal cramping, nausea, vomiting, diarrhea, skin rashes, itching, heartburn, dizziness, or headache in some patients, but most reactions are mild and pass quickly.
PURPOSE:To obtain an artificial bone and an artificial tooth high in strength, small in strength deterioration even when immersed for a long time in a physiological salt water, and superior in organism adaptability by incorporating a specified amt. of modified calcium phosphate compound and organic polymer. CONSTITUTION:The artificial bone and the artificial tooth of the present invention are the complex composed of the calcium phosphate compound with its surface modified by a modifier and the organic polymer. The compounding ratio of the calcium phosphate compound and the organic polymer to reform the surface with the modifier must be the calcium phosphate compound 10-90% (volume ratio) and the organic polymer 90-10% (volume ratio) to reform the surface. When the compounding ratio is less than 10%, the organism adaptability of the artificial bone and the artificial tooth is worsened and the formation of the new-bone to the periphery is hardly confirmed. On the other hand, when the ratio exceeds 90%, the processing of the artificial bone and the artificial tooth becomes harder. Thus, the artificial bone and artificial tooth, in which the strength is high and the strength deterioration is small even when they are immersed in the physiological salt water for a long time, can be obtained.
Eligible volunteers are randomly assigned to a treatment group consisting of a pre-packaged, portion controlled meal plan plus a group behavior modification program or to a control group that consists of a group diabetes support and education (DSE) program. Random assignment will be stratified by whether or not a subject is taking insulin at baseline, which will be included as a covariate in all subsequent analyses. Treatment assignments are unmasked. At the end of 24 weeks both groups will have completed 9 group sessions (weeks 0, 1, 2, 4, 8, 12, 16, 20 and 24). At week 16, each participant will meet individually with the study physician to review their progress to date. These meetings will take place at the week 16 group visit. The PCD program is aimed at achieving and maintaining a decrease in weight and providing a group behavior modification program from 0-24 weeks. The DSE program is aimed at providing diabetes support and education from weeks 0-24. A Certified Diabetes Educator (CDE) will review the effects of diet and weight loss, exercise, and medications on blood glucose levels among all participants at the individual session before any changes in dietary intake or exercise are prescribed. Participants will be counseled on strategies to prevent hypoglycemia and will be given a blood glucose meter and strips and instructed to measure their blood glucose at least two times per day while participating in the study. In addition, the causes, symptoms and treatment of hypoglycemia will be reviewed including when to contact their health care provider.
Breast cancer is extremely rare before the age of 25. It reaches a high incidence in the decade from 40 to 50 and continuous to increase in the frequency into old age. Mastectomy is the traditional approach to remove the entire breast once the diagnosis was confirmed. The most common cancers are lung cancer in men and breast cancer in women, however despite the large numbers of people affected by cancer there is very little literature on the role of physiotherapists in cancer care. After mastectomy and the accompanying excision or radiation of adjacent axillary lymph nodes a patient is at risk of developing upper extremity lymphedema, shoulder pain and loss of shoulder motion.low-level laser light waves penetrate deeply into the skin, they optimize the immune responses of our blood. This has both anti-inflammatory and immunosuppressive effects. It is a scientific fact that light transmitted to the blood in this way has positive effects throughout the whole body, supplying vital oxygen and energy to every cell .Electrical stimulation is based on the fact that human body has an endogenous bioelectric system that enhances healing of bone fracture, soft tissue lesions and decreasing post-operative pain. The external current may serve to mimic the failed natural bioelectric currents, so that post-operative pain can be inhibited. It was reported that microcurrent electrical neuromuscular stimulation (MENS) is better in enhancing cellular physiology processes than other current of higher amplitude, microcurrent is effective in the management of open wounds, inflammation and pain. sixty patients will be randomly allocated to three groups; first one will receive laser+ traditional therapy, second one will receive microcurrent + traditional therapy and third one will receive traditional therapy three times a week for three months.
One aspect of the present invention relates to compounds that are active at a peroxisome proliferator-activated receptor (PPAR). In certain embodiments, the compound has a isoxazole or indole core. Another aspect of the present invention relates to a method of treating a mammal afflicted with cancer or non-insulin-dependent (type II) diabetes by administering a therapeutic amount of the compounds of the invention. In certain embodiments, the invention relates to a method of treating prostrate, stomach, or breast cancer. Another aspect of the invention relates to a method of identifying ligands active at a PPAR subtype using X-ray structural information. In certain embodiments, the method of identifying the ligand comprises using molecular modeling approaches including: in silico screening of chemical databases, de novo/rational drug design in which the ligand will be created computationally, and/or in silico screening of virtual combinatorial libraries.
Previously, we reported that epidermal growth factor-like module-containing mucin-like hormone receptor-like 1 (EMR1/ADGRE1) is abnormally expressed in colon cancer (CC) and is a risk factor for lymph node metastasis (LNM) and poor recurrence-free survival in patients with abundant tumor-associated macrophages (TAMs). However, the signaling pathways associated with EMR1 expression in CC progression remain unclear. In this study, we aimed to explore the role of EMR1 and its signaling interactions with macrophages in CC progression. Spatial transcriptomics of pT3 microsatellite unstable CC tissues revealed heightened Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling in EMR1-HL CC with LNM compared to EMR1-N CC without LNM. Through in vitro coculture of CC cells with macrophages, EMR1 expression by CC cells was found to be induced by TAMs, ultimately interacting with upregulated JAK/STAT signaling, increasing cell proliferation, migration, and motility, and reducing apoptosis. JAK2/STAT3 inhibition decreased the levels of EMR1, JAK2, STAT1, and STAT3, significantly impeded the proliferation, migration, and mobility of cells, and increased the apoptosis of EMR1+ CC cells compared to their EMR1KO counterparts. Overall, TAMs-induced EMR1 upregulation in CC cells may promote LNM and CC progression via JAK2/STAT1,3 signaling upregulation. This study provides further insights into the molecular mechanisms involving macrophages and intracellular EMR1 expression in CC progression, suggesting its clinical significance and offering potential interventions to enhance patient outcomes.
Patients will be followed for 3 months before bone marrow aspiration (BMA). Patients will receive 2 intrathecal MSC injections, 1 and 2 months after BMA. The patients will be followed for 6 months after the interventions.
A gas delivery device includes a nitric oxide generating system. The system has a medium including a source of nitrite ions. A working electrode is in contact with the medium. A Cu(II)-ligand complex is in contact with the working electrode. A reference/counter electrode is, or a reference electrode and a counter electrode are in contact with the medium and separated from the working electrode. An inlet conduit is to deliver nitrogen gas to the medium, and an outlet conduit is to transport a stream of nitrogen gas and nitric oxide from the medium. An inspiratory gas conduit is operatively connected to the outlet conduit to introduce an oxygen-containing gas and form an output gas stream of the gas delivery device.
From the 2nd to 5th day of hospitalization, once a day, 4 times of non-resistance therapy is administered. And non-resistance therapy group is also treated with other Korean integrative medicine treatment everyday: acupuncture, chuna, pharmacoacupuncture and Korean herbal medicine.